Moody's Investors Service has assigned a "Baa2" rating to Boston Medical Center's proposed $180 million of series 2016E revenue bonds.
The rating assignment is based on several factors, including Boston Medical Center's key role as a healthcare provider in the area and as a provider of health insurance services through an affiliated insurance plan.
BMC also faces challenges, including a payer mix heavily weighted toward governmental payers.
The outlook is stable, reflecting Moody's Investors Services' view that BMC will continue to receive supplemental funding and generate adequate margins.